Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +75

Gilead Sciences (GILD) Receives a Buy from Citi

AI-generated analysis

πŸ“ˆ Citi analyst Geoff Meacham maintained a Buy rating on Gilead Sciences (GILD) with a price target of $165.00.

πŸ’° The company reported quarterly revenue of $6.96 billion and net profit of $2.02 billion for the quarter ending March 31.

πŸ“Š Revenue increased from $6.67 billion last year, while net profit rose significantly from $1.32 billion in the prior year.

🏦 Wells Fargo analyst Mohit Bansal also issued a Buy rating on Gilead Sciences in a report released yesterday.

βš–οΈ RBC Capital maintained a Hold rating on Gilead Sciences as of June 1, contrasting with the recent upgrades.

πŸ‘¨β€πŸ’Ό Analyst Geoff Meacham covers the Healthcare sector and has an average return of 8.6% on recommended stocks.

πŸ”¬ Recent headlines highlight Gilead's Phase 3 study results for Livdelzi and new data presented at the EASL congress.

πŸ“° The article notes that Gilead is trending alongside other companies like Eli Lilly, Merck, and Pfizer in analyst coverage.

Bullish Signals
  • Citi analyst Geoff Meacham maintained a Buy rating on Gilead Sciences (GILD) with a price target of $165.00.
  • Wells Fargo's Mohit Bansal also issued a Buy rating on Gilead Sciences in a report released yesterday.
  • Gilead reported quarterly revenue of $6.96 billion, representing growth from last year's revenue of $6.67 billion.
  • The company achieved a net profit of $2.02 billion for the quarter ending March 31, up significantly from $1.32 billion in the same period last year.
Risk Factors
  • RBC Capital maintained a Hold rating on Gilead Sciences (NASDAQ: GILD) as of June 1, indicating some analysts are not bullish enough to recommend buying the stock.
Full Analysis
Citi analyst Geoff Meacham maintained a Buy rating on Gilead Sciences (GILD) with a price target of $165.00, based on the company's latest earnings release for the quarter ending March 31. The report highlights that Gilead reported quarterly revenue of $6.96 billion and net profit of $2.02 billion, compared to last year's revenue of $6.67 billion and net profit of $1.32 billion. In addition to Citi, Wells Fargo analyst Mohit Bansal also issued a Buy rating on Gilead Sciences in a report from yesterday, while RBC Capital maintained a Hold rating as of June 1. The article notes that Meacham covers the Healthcare sector and has an average return of 8.6% with a 54.62% success rate on recommended stocks.